Clinical Trials in Progress: Bladder Cancer
Sunday, May 17, 2026 9:00 AM to 11:00 AM · 2 hr. (America/New_York)
Hall B, The Square, Learning Lab
Learning Lab
New Technologies/Instruments/DevicesOncology: Bladder
Information
Of Interest To
Researchers
Sunday, May 17
Safety and Efficacy of Bel-sar (AU-011), a Virus-Like Drug Conjugate, in Participants with Non-Muscle Invasive Bladder Cancer (NMIBC)
Sunday, May 17, 2026 9:00 AM to 9:08 AM
Hall B, The Square, Learning Lab
SWOG S2611 (ARCIS) A Randomized Comparison of Intravesical Therapies: A phase III study of cretostimogene grenadenorepvec/gemcitabine (CRETO-GEM) versus gemcitabine/docetaxel (GEM-DOCE) for the treatment of BCG-unresponsive and BCG-exposed NMIBC
Sunday, May 17, 2026 9:08 AM to 9:16 AM
Hall B, The Square, Learning Lab
ENLIGHTED Phase 3 Trial of Non-Thermal, Drug-Activated Padeliporfin Vascular-Targeted Photodynamic Therapy (VTP) for Low-Grade Upper Tract Urothelial Carcinoma (LG UTUC)
Sunday, May 17, 2026 9:16 AM to 9:24 AM
Hall B, The Square, Learning Lab
A Phase II Study of Intravesical HM-001 in Patients with Non–Muscle-Invasive Bladder Cancer Following Safe Completion of a Phase I Trial
Sunday, May 17, 2026 9:24 AM to 9:32 AM
Hall B, The Square, Learning Lab
A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants with FGFR3-Altered Low-Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)
Sunday, May 17, 2026 9:32 AM to 9:40 AM
Hall B, The Square, Learning Lab
MoonRISe-2, a Phase 2 Dose Expansion Within the Study of Erdafitinib Intravesical Drug Releasing System (TAR-210) for Localized Bladder Cancer: Study Design and Baseline Characteristics
Sunday, May 17, 2026 9:40 AM to 9:48 AM
Hall B, The Square, Learning Lab
MoonRISe-3: a phase 3 study of erda-iDRS, an erdafitinib intravesical drug-releasing system, vs intravesical chemotherapy in patients with bacillus Calmette-Guérin–treated high-risk non–muscle-invasive bladder cancer with susceptible FGFR alterations
Sunday, May 17, 2026 9:48 AM to 9:56 AM
Hall B, The Square, Learning Lab
Trial in Progress: REL-NDV01-301 (BOOST) - A Phase 3, Randomized Study of Adjuvant Intravesical Sustained-Release Gemcitabine-Docetaxel (NDV-01) Versus Surveillance for the Treatment of Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Sunday, May 17, 2026 9:56 AM to 10:04 AM
Hall B, The Square, Learning Lab
A phase 1/2 study of intravesical MK-3120 in participants with Bacillus Calmette-Guérin (BCG)-Naive or BCG-exposed high-risk non–muscle invasive bladder cancer
Sunday, May 17, 2026 10:04 AM to 10:12 AM
Hall B, The Square, Learning Lab
THE GAIN TRIAL: Gemcitabine Alternating with INtravesical BCG randomized against BCG alone for patients with recurrent “BCG-exposed” high grade NMIBC (ALLIANCE A032303/ NCT07000084)
Sunday, May 17, 2026 10:12 AM to 10:20 AM
Hall B, The Square, Learning Lab
HIVEC®-HEAT (Hyperthermic intravesical mitomycin [Mitomycin medac]) for patients with BCG-unresponsive nonmuscle-invasive bladder cancer trial
Sunday, May 17, 2026 10:20 AM to 10:28 AM
Hall B, The Square, Learning Lab
Gastrointestinal Recovery After Radical Cystectomy: Coffee Or Entereg For Enhanced Recovery (GI-COFEE) Trial
Sunday, May 17, 2026 10:28 AM to 10:36 AM
Hall B, The Square, Learning Lab
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy: The Randomized TIDE (Timed Intravenous Fluid Delivery for ERAS) Trial
Sunday, May 17, 2026 10:36 AM to 10:44 AM
Hall B, The Square, Learning Lab
The phase 1/2 ResQ133A-NMIBC trial: A study of intravesical recombinant Mycobacterium Bacillus Calmette‑Guérin (rBCG) in BCG‑naïve participants with non‑muscle‑invasive bladder cancer (NMIBC)
Sunday, May 17, 2026 10:44 AM to 10:52 AM
Hall B, The Square, Learning Lab
